Established in 1994 and headquartered in Riyadh, Tabuk Pharmaceuticals is a leading private sector pharmaceutical company in the Kingdom of Saudi Arabia, with a strong and growing presence across the MENA region.
Tabuk Pharmaceuticals specialises in the development, manufacturing, marketing, and distribution of a wide range of branded pharmaceutical products. In addition to producing pharmaceutical products for international and regional partners at its facilities within the Kingdom of Saudi Arabia, the company also grants licenses to business partners across the Kingdom and the broader MENA region, enabling them to manufacture and market its products.
Research and development are a core part of Tabuk Pharmaceuticals’ commitment to promoting well-being and improving healthcare outcomes across societies. Its state-of-the-art R&D department, supported by a team of experts, develops advanced solutions to produce medicines for various therapeutic areas, including cardiovascular, respiratory, central nervous, musculoskeletal, and gastrointestinal systems, as well as anti-infectives, pain management medications, and diabetes. Tabuk Pharmaceuticals also collaborates with global healthcare leaders like Abbott, Biocon, Lupin, AstraZeneca, Moderna, and Novartis.
With a workforce of over 2,400 professionals across four advanced manufacturing sites in Saudi Arabia’s Tabuk and Dammam, Sudan, and Algeria, the company produces over two billion base units annually to help maintain the health of millions of patients across 17 countries in the MENA region. Armed with the vision of being a leading pharmaceutical company valued for its trusted and diversified products, Tabuk Pharmaceuticals continues to invest in differentiated technologies to deliver high-quality, affordable generic medicines for better global healthcare.
Tabuk Pharmaceuticals places a strong emphasis on pharmacovigilance, reflecting its commitment to minimising potential adverse effects associated with medication use and supporting patient safety.
Recognising the importance of sustainability in supporting long-term resilience for both its business and the wider community, Tabuk Pharmaceuticals continues to integrate responsible practices across its operations, with a focus on efficiency, compliance, and reducing environmental impact.
Tabuk Pharmaceuticals has been a proud participant in the American Chemistry Council (ACC) Responsible Care® initiative. Through its involvement in the Responsible Care® initiative and the Responsible Care® Global Charter, the company joins the global commitment of the pharmaceutical and chemical industries to enhance environmental, health, safety, and security performance. In alignment with this commitment, the company fully embraces and pledges to uphold the guiding principles across all aspects of its business operations.
As a leading pharmaceutical company in Saudi Arabia, Tabuk Pharmaceuticals is committed to supporting the objectives of Saudi Vision 2030, contributing to the advancement of the domestic healthcare industry and strengthening local pharmaceutical manufacturing capabilities. The company aims to reinforce its position as a trusted partner to the government health sector, private healthcare providers, and patients while continuing to make a significant impact on regional healthcare systems.